HOME
OVERVIEW
LEGAL SERVICES
INTELLECTUAL PROPERTY
TEAM
CASES
BLOG
CONTACT US
Authorization and Confirmation
Litigation
Rights Protection and Crackdown
Yongding Case | The "Pseudo-Health" Trap Under Health Anxiety: A Lesson Bought for 450,000, Court Mediation Result Shines!
In recent years, China's health supplement market has continued to develop rapidly. According to industry statistics, the current market size has exceeded 200 billion yuan. However, behind the market prosperity, the issue of ordinary foods falsely advertising health benefits has become increasingly prominent. The annual report of the China Consumers Association points out that complaints of this kind have increased by 63% compared to the previous year, with cases involving medical claims such as "blood sugar reduction" and "detoxification" accounting for nearly 80%. These products often wear a "technological facade" and precisely target people anxious about their health through sales meetings, live broadcasts, and other scenarios. Elderly consumers, due to insufficient awareness of the "Blue Hat" label (awareness rate only 42%), are more likely to fall into carefully designed verbal traps. Recently, a case involving a technology company suspected of false advertising of health supplements (involving 450,000 yuan) has attracted widespread attention in the industry, reflecting typical legal risks in current food marketing and advertising.
Yongding Case | "Peppa Pig" Trademark Cross-Class Infringement Case: The Logic Behind Famous Trademark Protection in Compensation!
In 2000, three British animators—Neville Astley, Mark Baker, and Phil Davies—tired of the trend in animation focusing on complex plots and special effects, decided to create a work that would "truly relax children." They based the character Peppa on a pink pig toy from Mark's daughter's bookshelf, designing Peppa with a round face, a snout like a hairdryer, and a height of only seven heads tall.
Yongding Case | "Chang Xiulin" Trademark Infringement Case Verdict: A One-Character Difference Results in 60 Million Compensation! Pharmaceutical Giant Maliciously "Riding on a Famous Brand" Ordered to Pay a Sky-High Compensation, Pharmaceutical Intellectual Property Protection Upgraded Again
In the context of increasingly fierce global competition in pharmaceutical industry innovation and the accelerated transformation and upgrading of China's pharmaceutical industry, intellectual property protection has become a key guarantee for promoting pharmaceutical innovation. The Chinese insulin market has long been monopolized by multinational pharmaceutical companies until 2002, when Company A successfully developed the first domestically produced third-generation insulin—"Changxiulin" (Insulin Glargine Injection), breaking this monopoly. Recently, the trademark infringement and unfair competition dispute case between Company A and Company B concluded, with the court fully supporting the plaintiff's claim for 60 million yuan in compensation. This case not only set a new record for trademark infringement compensation in the domestic insulin field but also attracted significant attention due to its relevance to the pharmaceutical industry's special nature and public health safety.